MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $83.09 (49.58% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetActions
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016WedbushReiterated RatingOutperform$113.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016MizuhoInitiated CoverageBuy$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Brean CapitalReiterated RatingBuy$92.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Bank of AmericaUpgradeNeutral -> Buy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Piper JaffrayReiterated RatingOverweight$93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015BarclaysReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Jefferies GroupReiterated RatingBuy$81.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015Goldman SachsBoost Price Target$126.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 4/29/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha